COMMUNIQUÉS West-GlobeNewswire

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
09/10/2025
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the [...]
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial
09/10/2025
STAFFORD, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
09/10/2025
Acquisition adds potential first- and best-in-class asset, enhancing Novo Nordisk’s portfolio for treatment of MASH, one of the most prevalent obesity related comorbidities Akero Therapeutics’s FGF21 analogue [...]
Human Appeal's Pot of Gold Film to Air on EarthX Channel on October 18
09/10/2025
BayView Entertainment to Bring Groundbreaking Documentary to Streaming and Broadcast Audiences MISSION VIEJO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pot of Gold , a powerful independent documentary set in the [...]
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
09/10/2025
Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share Advances Akero’s Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE [...]
U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade
09/10/2025
Ingelheim, Germany/Ridgefield, Connecticut, U.S. Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function. 1 Approval is based on results from two clinical trials, [...]
Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform
09/10/2025
ACTON, Mass. and YAMANASHI, Japan, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), a medical diagnostics company focused on developing rapid near-patient testing solutions for [...]
Genvor Restores Trading Status and Expands Global Collaborative Research Network
09/10/2025
Woodland, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCID: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced that it has regained active OTCQB trading status on [...]
Dr. Mark Hyman joins ADvantage Therapeutics Advisory Board to further advance Klotho-Based Longevity Programs at Klothea Bio
09/10/2025
World-renowned longevity physician to help guide Klothea Bio as it prepares for a Phase 1B clinical trial of its Klotho therapeutic for aging related diseases MIAMI, Oct. 09, 2025 (GLOBE NEWSWIRE) -- ADvantage [...]
Tilray Brands Reports Strong First Quarter Fiscal 2026 Results, Highlighting Continued Growth with Record Q1 Net Revenue of $210 Million and Net Income
09/10/2025
Operational Efficiencies and Focus on Profitability Drove Net Income of $1.5 Million, Adjusted EBITDA Increased 9% to $10 Million and Net Cash Used in Operations Improved by $34 Million Year-Over-Year Canadian Adult-Use [...]
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
09/10/2025
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is [...]
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
09/10/2025
Event to be held October 14th at 4 p.m. EST BETHESDA, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the [...]
Humber River Health Achieves Excellent Scores, Remarkably Low Rate of Patient Harm, Leading Provincial and National Benchmarks
09/10/2025
TORONTO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Humber River Health has reported a significantly lower rate of patient harm compared to both provincial and national averages, underscoring the organization’s commitment to [...]
Grow Up Conference & Expo Debuts in Vancouver
09/10/2025
B2B cannabis event returns to B.C. for three days of education and business-building Vancouver, B.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Grow Up Conference & Expo (“Grow Up”), Canada’s largest B2B cannabis event, [...]
Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025
09/10/2025
CHATHAM, N.J., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biotechnology company with marketed products and a pipeline of [...]
GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress
09/10/2025
DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in [...]
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
09/10/2025
Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17 th Captisol-enabled™ approved product JUPITER, Fla., Oct. 09, 2025 ( [...]
60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
09/10/2025
Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competition A $5K donation from the Company was split between ILADEF and GLA to recognize the winning name B-FREE, a [...]
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
09/10/2025
– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the Phase 2 trial results – – State-of-the-art neuroimaging and biomarker [...]

Pages